See more : Novartis AG (NVS) Income Statement Analysis – Financial Results
Complete financial analysis of Certara, Inc. (CERT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Certara, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- China United Insurance Service, Inc. (CUII) Income Statement Analysis – Financial Results
- Atlas Financial Holdings, Inc. (AFHIF) Income Statement Analysis – Financial Results
- Sebino S.p.A. (SEB.MI) Income Statement Analysis – Financial Results
- Digital Holdings, Inc. (2389.T) Income Statement Analysis – Financial Results
- LPKF Laser & Electronics AG (LPK.DE) Income Statement Analysis – Financial Results
Certara, Inc. (CERT)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.certara.com
About Certara, Inc.
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 354.34M | 335.64M | 286.10M | 243.53M | 208.51M | 163.72M |
| Cost of Revenue | 141.02M | 132.58M | 111.62M | 100.77M | 79.77M | 71.04M |
| Gross Profit | 213.32M | 203.07M | 174.49M | 142.77M | 128.74M | 92.68M |
| Gross Profit Ratio | 60.20% | 60.50% | 60.99% | 58.62% | 61.74% | 56.61% |
| Research & Development | 34.17M | 28.21M | 20.38M | 19.64M | 11.63M | 10.48M |
| General & Administrative | 95.39M | 71.77M | 79.54M | 88.48M | 47.93M | 43.39M |
| Selling & Marketing | 32.02M | 27.41M | 20.14M | 19.20M | 10.73M | 9.42M |
| SG&A | 127.41M | 99.18M | 99.68M | 107.68M | 58.66M | 52.81M |
| Other Expenses | 92.51M | 43.16M | 40.85M | 39.86M | 38.84M | -107.00K |
| Operating Expenses | 254.09M | 170.55M | 160.91M | 167.19M | 109.13M | 97.33M |
| Cost & Expenses | 395.11M | 303.12M | 272.53M | 267.95M | 188.90M | 168.37M |
| Interest Income | 0.00 | 17.77M | 16.84M | 25.30M | 28.00M | 0.00 |
| Interest Expense | 22.92M | 17.77M | 16.84M | 25.30M | 28.00M | 27.80M |
| Depreciation & Amortization | 56.07M | 52.47M | 45.12M | 42.75M | 41.56M | 37.01M |
| EBITDA | 23.84M | 89.00M | 58.58M | 17.87M | 60.41M | 32.25M |
| EBITDA Ratio | 6.73% | 26.52% | 20.47% | 7.34% | 28.97% | 19.70% |
| Operating Income | -40.77M | 32.52M | 13.58M | -24.89M | 19.61M | -4.65M |
| Operating Income Ratio | -11.51% | 9.69% | 4.75% | -10.22% | 9.41% | -2.84% |
| Total Other Income/Expenses | -14.37M | -13.77M | -16.95M | -25.76M | -28.76M | -27.91M |
| Income Before Tax | -55.14M | 18.76M | -3.38M | -50.18M | -9.15M | -32.56M |
| Income Before Tax Ratio | -15.56% | 5.59% | -1.18% | -20.61% | -4.39% | -19.89% |
| Income Tax Expense | 214.00K | 4.02M | 9.89M | -784.00K | -225.00K | 697.00K |
| Net Income | -55.36M | 14.73M | -13.27M | -49.40M | -8.93M | -33.26M |
| Net Income Ratio | -15.62% | 4.39% | -4.64% | -20.28% | -4.28% | -20.31% |
| EPS | -0.35 | 0.09 | -0.09 | -0.32 | -0.06 | -0.25 |
| EPS Diluted | -0.35 | 0.09 | -0.09 | -0.32 | -0.06 | -0.25 |
| Weighted Avg Shares Out | 158.94M | 156.88M | 149.84M | 152.98M | 157.34M | 132.41M |
| Weighted Avg Shares Out (Dil) | 158.94M | 159.35M | 149.84M | 152.98M | 157.34M | 132.41M |
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
Certara Inc. (CERT) Q3 2023 Earnings Call Transcript
Certara, Inc. (CERT) Q3 Earnings Meet Estimates
Certara Reports Third Quarter 2023 Financial Results
Circling Back On Certara
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Source: https://incomestatements.info
Category: Stock Reports